<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04371666</url>
  </required_header>
  <id_info>
    <org_study_id>FGCL-3019-093</org_study_id>
    <nct_id>NCT04371666</nct_id>
  </id_info>
  <brief_title>A Phase 3 Trial of Pamrevlumab or Placebo in Combination With Systemic Corticosteroids, in Subjects With Non-ambulatory Duchenne Muscular Dystrophy (DMD)</brief_title>
  <official_title>A Phase 3, Randomized, Double-Blind, Trial of Pamrevlumab (FG-3019) or Placebo in Combination With Systemic Corticosteroids in Subjects With Non-ambulatory Duchenne Muscular Dystrophy (DMD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>FibroGen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>FibroGen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the efficacy and safety of pamrevlumab versus placebo in combination with&#xD;
      systemic corticosteroids in subjects with non-ambulatory Duchenne muscular dystrophy (age 12&#xD;
      years and older).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a global, randomized, double-blind trial of pamrevlumab or placebo in combination&#xD;
      with systemic corticosteroids in subjects with non-ambulatory Duchenne muscular dystrophy,&#xD;
      aged 12 years and older. Approximately 90 male subjects will be randomized at a 1:1 ratio to&#xD;
      Arm A (pamrevlumab + systemic corticosteroid) or Arm B (placebo+ systemic corticosteroid),&#xD;
      respectively.&#xD;
&#xD;
      Subjects must be fully informed of the potential benefits of approved products and make an&#xD;
      informed decision that they prefer to participate in a clinical trial in which they could be&#xD;
      randomized to placebo.&#xD;
&#xD;
      Subjects will be randomized in a 1:1 ratio to one of the two study treatment arms;&#xD;
      pamrevlumab or placebo in combination with systemic steroids.&#xD;
&#xD;
      This trial has three study periods:&#xD;
&#xD;
        -  Screening period: Up to 4 weeks&#xD;
&#xD;
        -  Treatment period: 52 weeks&#xD;
&#xD;
        -  Safety Follow-up period/final assessment: 4 weeks (Week 56 (+/-3 days))&#xD;
&#xD;
      In the screening period, subjects will be evaluated per the protocol inclusion/exclusion&#xD;
      criteria to determine eligibility for participation in this trial.&#xD;
&#xD;
      During the treatment period, each subject will receive pamrevlumab or placebo at 35 mg/kg&#xD;
      every 2 weeks for up to 52 weeks.&#xD;
&#xD;
      Subjects who complete the 52-week study (either arm) may be eligible for rollover into an&#xD;
      open-label extension treatment (OLE) with pamrevlumab + systemic corticosteroids.&#xD;
&#xD;
      Subjects who discontinue study treatment for any reason should be encouraged to return to the&#xD;
      investigative site to complete final safety and efficacy assessments.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 30, 2020</start_date>
  <completion_date type="Anticipated">September 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Functional assessment: Change in the total score of Performance of Upper Limb (PUL) 2.0 version</measure>
    <time_frame>Baseline to Week 52</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pulmonary assessment: Change in percent predicted forced vital capacity (ppFVC) assessed by spirometry.</measure>
    <time_frame>baseline to Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary assessment: Change in percent predicted peak expiratory flow (ppPEF) assessed by spirometry</measure>
    <time_frame>baseline to Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Performance assessment: Change in the Grip strength of the hands assessed by Hand Held Myometry (HHM).</measure>
    <time_frame>baseline to Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac assessment: Change in Left Ventricular Ejection Fraction percentage (LVEF %) assessed by MRI.</measure>
    <time_frame>baseline to Week 52</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Duchenne Muscular Dystrophy</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>pamrevlumab 35 mg/kg IV Q2 weeks + systemic deflazacort or equivalent potency of corticosteroids administered orally</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>matching placebo IV Q2 weeks + systemic deflazacort or equivalent potency of corticosteroids administered orally</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pamrevlumab</intervention_name>
    <description>pamrevlumab 35 mg/kg IV Q2 weeks + systemic deflazacort or equivalent potency of corticosteroids administered orally</description>
    <arm_group_label>Arm A</arm_group_label>
    <other_name>FG-3019</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>matching placebo IV Q2 weeks + systemic deflazacort or equivalent potency of corticosteroids administered orally</description>
    <arm_group_label>Arm B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Males at least 12 years of age, non-ambulatory at screening initiation&#xD;
&#xD;
          2. Written consent by patient and/or legal guardian as per regional/ country and/or&#xD;
             IRB/IEC requirements&#xD;
&#xD;
          3. Male subjects with partners of childbearing potential must use contraception during&#xD;
             the conduct of the study, and for 3 months after the last dose of study drug.&#xD;
&#xD;
          4. Medical history includes diagnosis of DMD and confirmed Duchenne mutation using a&#xD;
             validated genetic test&#xD;
&#xD;
          5. Brooke Score for Arms and Shoulders ≤5&#xD;
&#xD;
          6. Able to undergo MRI test for the upper arm extremities (Biceps Brachii muscle) and&#xD;
             cardiac muscle&#xD;
&#xD;
          7. Able to perform spirometry&#xD;
&#xD;
          8. Average (of Screening and Day 0) percent predicted FVC between 45 and 85, inclusive&#xD;
&#xD;
          9. Left ventricular ejection fraction ≥50% as determined by cardiac MRI at screening or&#xD;
             within 3 months prior to randomization (Day 0)&#xD;
&#xD;
         10. Prior diagnosis of cardiomyopathy, subjects must be on a stable regimen dose for&#xD;
             cardiomyopathy/ heart failure medications (e.g., angiotensin converting enzyme&#xD;
             inhibitors, aldosterone receptors blockers, angiotensin-receptor blockers, and&#xD;
             betablockers) for at least 1 month prior to screening&#xD;
&#xD;
         11. On a stable dose of systemic corticosteroids for a minimum of 6 months, with no&#xD;
             substantial change in dosage for a minimum of 3 months (except for adjustments for&#xD;
             changes in body weight) prior to screening. Corticosteroid dosage should be in&#xD;
             compliance with the DMD Care Considerations Working Group recommendations&#xD;
             (e.g.prednisone or prednisolone 0.75 mg/kg per day or deflazacort 0.9 mg/kg per day)&#xD;
             or stable dose. A reasonable expectation is that dosage and dosing regimen would not&#xD;
             change significantly for the duration of the study.&#xD;
&#xD;
         12. Received pneumococcal vaccine (PPSV23) (or any other pneumococcal polysaccharide&#xD;
             vaccine as per national recommendations) and is receiving annual influenza&#xD;
             vaccinations&#xD;
&#xD;
         13. Adequate renal function: cystatin C ≤1.4 mg/L&#xD;
&#xD;
         14. Adequate hematology and electrolytes parameters:&#xD;
&#xD;
               1. Platelets &gt;100,000/mcL&#xD;
&#xD;
               2. Hemoglobin &gt;12 g/dL&#xD;
&#xD;
               3. Absolute neutrophil count &gt;1500 /μL&#xD;
&#xD;
               4. Serum calcium (Ca), potassium (K), sodium (Na), magnesium (Mg) and phosphorus (P)&#xD;
                  levels are within a clinically accepted range&#xD;
&#xD;
         15. Adequate hepatic function:&#xD;
&#xD;
               1. No history or evidence of liver disease&#xD;
&#xD;
               2. Gamma glutamyl transferase (GGT) ≤3x upper limit of normal (ULN)&#xD;
&#xD;
               3. Total bilirubin ≤1.5xULN&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Previous exposure to pamrevlumab&#xD;
&#xD;
          2. BMI ≥40 kg/m2 or weight &gt;117 kg&#xD;
&#xD;
          3. History of allergic or anaphylactic reaction to human, humanized, chimeric or murine&#xD;
             monoclonal antibodies&#xD;
&#xD;
          4. Exposure to any investigational drug (for DMD or not), in the 30 days prior to&#xD;
             screening initiation or use of approved DMD therapies (e.g., eteplirsen, ataluren,&#xD;
             golodirsen) within 5 half-lives of screening, whichever is longer, with the exception&#xD;
             of the systemic corticosteroids, including deflazacort&#xD;
&#xD;
          5. Severe uncontrolled heart failure (NYHA Classes III-IV), including any of the&#xD;
             following:&#xD;
&#xD;
               1. Need for intravenous diuretics or inotropic support within 8 weeks prior to&#xD;
                  screening&#xD;
&#xD;
               2. Hospitalization for a heart failure exacerbation or arrhythmia within 8 weeks&#xD;
                  prior to screening&#xD;
&#xD;
          6. Arrhythmia requiring anti-arrhythmic therapy&#xD;
&#xD;
          7. Requires ≥16 hours continuous ventilation&#xD;
&#xD;
          8. Hospitalization due to respiratory failure within the 8 weeks prior to screening&#xD;
&#xD;
          9. Poorly controlled asthma or underlying lung disease such as bronchitis,&#xD;
             bronchiectasis,emphysema, recurrent pneumonia that in the opinion of the investigator&#xD;
             might impact respiratory function&#xD;
&#xD;
         10. The Investigator judges that the subject will be unable to fully participate in the&#xD;
             study and complete it for any reason, including inability to comply with study&#xD;
             procedures and treatment, or any other relevant medical or psychiatric conditions&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jessica Charpentier</last_name>
    <phone>415.978.1346</phone>
    <email>LELANTOS@fibrogen.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Arkansas Children's</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Aravindhan Veerapandiyan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California Los Angeles Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Stanley Nelson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UC Davis Health</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Craig McDonald</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Joanne Janas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rare Disease Research, LLC</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30318</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Han Phan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ann &amp; Robert H. Lurie Children's Hospital of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Vamshi Rao</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Iowa</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Katherine Mathews</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Kansas Medical Center</name>
      <address>
        <city>Fairway</city>
        <state>Kansas</state>
        <zip>66205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jeffrey Statland</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kennedy Krieger Institute</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Doris Leung</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UMASS Med School</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01655</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Brenda Wong</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>C.S. Mott Children's Hospital</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109-4234</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Erin Knierbein</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Spectrum Health Hospitals Helen DeVos Children's Hospital</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49503</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jena Krueger</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine in Saint Louis</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Craig Zaidman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Carolinas HealthCare System Neurosciences Institute-Neurology - Charlotte</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28207</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Urvi Desai</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Cuixia Tian</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nationwide Children's Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43205-2664</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Anne Connolly</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shriners Hospital for Children</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Erika Finanger</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Penn State Health Children's Hospital</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ashutosh Kumar</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>John Brandsema</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>William Burnette</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Health Dallas/UTSW</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75207</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Diana Castro</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Specialty Group - Medical Center Office</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Crystal Proud</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seattle Children's Hospital</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Seth Perlman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Murdoch Children's Research Institute</name>
      <address>
        <city>Parkville</city>
        <state>Victoria</state>
        <zip>3052</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Monique Ryan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinik Favoriten</name>
      <address>
        <city>Vienna</city>
        <zip>1100</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Günther Bernert</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Gent</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Nicolas Deconinck</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Leuven - Campus Gasthuisberg</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Liesbeth De Waele</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Régional de la Citadelle</name>
      <address>
        <city>Liège</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Stéphanie Delstanche</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>London Health Sciences Centre</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5W9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Craig Campbell</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Montreal Neurological Institute and Hospital</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H3A 2B4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Erin O'Ferrall</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fakultní Nemocnice Brno - Dětská Nemocnice</name>
      <address>
        <city>Brno</city>
        <zip>613 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Pavlína Danhofer</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinika dÄ&gt;tské neurologie, Neuromuskulární centrum</name>
      <address>
        <city>Prague</city>
        <zip>150 06</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jana Haberlová</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Nantes - Hotel Dieu</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Yann Pereon</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Association Institut de Myologie</name>
      <address>
        <city>Paris</city>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Silvana De Lucia, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Hautepierre</name>
      <address>
        <city>Strasbourg cedex</city>
        <zip>67098</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Vincent Laugel</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Chaim Sheba Medical Center</name>
      <address>
        <city>Tel Aviv</city>
        <zip>5265601</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Amir Dori</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Edith Wolfson Medical Center</name>
      <address>
        <city>Tel Aviv</city>
        <zip>5822012</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Mira Ginzberg</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Istituto di Ricovero e Cura a Carattere Scientifico Eugenio Medea - Lombardia</name>
      <address>
        <city>Lecco</city>
        <zip>23842</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Maria Grazia D'Angelo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IRRCS Ospedale San Raffaele</name>
      <address>
        <city>Milan</city>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Stefano Previtali</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fondazione Policlinico Universitario Agostino Gemelli</name>
      <address>
        <city>Rome</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Eugenio Maria Mercuri, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Pediatrico Bambino Gesù - Roma - Gianicolo</name>
      <address>
        <city>Rome</city>
        <zip>165</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Adele D'Amico</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Radboud Universitair Medisch Centrum</name>
      <address>
        <city>Nijmegen</city>
        <state>Gelderland</state>
        <zip>6525</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Saskia Houwen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Leiden Universitair Medisch Centrum</name>
      <address>
        <city>Leiden</city>
        <zip>2333 ZA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Erik Niks</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario de Alicante</name>
      <address>
        <city>Alicante</city>
        <zip>3010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Carmen Díaz Marín</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall d'Hebrón</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>David Gomez-Andrés</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari i Politecnic La Fe</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Nuria Muelas</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Inselspital Universitätsspital Bern</name>
      <address>
        <city>Bern</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Andrea Klein</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Leeds Teaching Hospitals NHS Trust</name>
      <address>
        <city>Leeds</city>
        <zip>LS1 3EX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Anne-Marie Childs</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Guy's and Saint Thomas' NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <zip>SE1 7EH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Vasantha Gowda</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University College London Hospitals NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <zip>WC1N</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Rosaline Quinlivan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oxford University Hospitals NHS Foundation Trust</name>
      <address>
        <city>Oxford</city>
        <zip>OX3 9DU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Stefen Brady</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Czechia</country>
    <country>France</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>April 29, 2020</study_first_submitted>
  <study_first_submitted_qc>April 29, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 1, 2020</study_first_posted>
  <last_update_submitted>October 19, 2021</last_update_submitted>
  <last_update_submitted_qc>October 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Duchenne Muscular Dystrophy, DMD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Muscular Dystrophies</mesh_term>
    <mesh_term>Muscular Dystrophy, Duchenne</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

